Scarica l'app Stockscreener
16.32
4.21%
0.66
Dopo l'orario di chiusura:
15.51
-0.81
-4.96%
Precedente Chiudi:
$15.66
Aprire:
$16
Volume 24 ore:
50,253
Relative Volume:
0.84
Capitalizzazione di mercato:
$27.20M
Reddito:
-
Utile/perdita netta:
$-4.85M
Rapporto P/E:
-23.27
EPS:
-0.7012
Flusso di cassa netto:
$-3.95M
1 W Prestazione:
-8.78%
1M Prestazione:
-5.45%
6M Prestazione:
+164.72%
1 anno Prestazione:
+133.38%
Intervallo 1D:
$15.64
$16.44
Intervallo di 1 settimana:
$15.52
$18.32
Portata 52W:
$5.40
$32.55
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Nome
Cadrenal Therapeutics Inc
Settore
Industria
Telefono
904-300-0701
Indirizzo
822 A1A NORTH, PONTE VEDRA
Confronta CVKD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CVKD | 16.32 | 27.20M | 0 | -4.85M | -3.95M | -0.7012 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cadrenal Therapeutics Inc Borsa (CVKD) Ultime notizie
(CVKD) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan
Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada
Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - PR Newswire
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat
Long Term Trading Analysis for (CVKD) - Stock Traders Daily
Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Where are the Opportunities in (CVKD) - Stock Traders Daily
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy - TipRanks
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - Kilgore News Herald
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
WATCH LIVE: Fed Chair Jerome Powell speaks after a 50bp interest rate cut - Investing.com
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data - MSN
Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting - Stocks Telegraph
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - MarketBeat
Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland - MSN
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Cadrenal Therapeutics regains Nasdaq compliance - Investing.com India
Cadrenal gears up for FDA talks on heart drug trial - Investing.com India
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients - PR Newswire
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients - PR Newswire
Upcoming Stock Splits This Week (August 19 to August 23) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - MSN
Cadrenal Therapeutics to Implement 1-for-15 Reverse Stock Split - Marketscreener.com
Cadrenal announces 1-for-15 reverse stock split By Investing.com - Investing.com Australia
Cadrenal announces 1-for-15 reverse stock split - Investing.com
Cadrenal Therapeutics Inc: Analyzing CVKD Stock Trends - The InvestChronicle
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cadrenal Therapeutics to Present at Upcoming Investor Conferences - Longview News-Journal
Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now - Yahoo Finance
Q3 2024 Earnings Estimate for Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Issued By HC Wainwright - Defense World
10 Best New Penny Stocks To Buy Now - Insider Monkey
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update - PR Newswire
Cadrenal Therapeutics Inc Azioni (CVKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):